834
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Are triplet therapies really living up to their hype as the “standard of care” for multiple myeloma and what else is needed?

&
Pages 699-701 | Received 21 May 2019, Accepted 05 Jul 2019, Published online: 16 Jul 2019
 

Declaration of interest

S Knop has received honoraria from Celgene, Janssen, BMS, Amgen and Takeda as well as travel grants from Celgene and Amgen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.